Showing 971-980 of 1226 results for "".
- GenSight Biologics to Present 72-Week Data From the REVERSE Phase 3 Trial of GS010https://modernod.com/news/gensight-biologics-to-present-72-week-data-from-the-reverse-phase-3-trial-of-gs010/2476389/GenSight Biologics announced that the 72-week results from the REVERSE Phase 3 clinical trial of GS010 will be presented at the 45th Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), which will be held in Las Vegas from March 16 to 21, 2019. The results will be presented b
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- Oculis Raises $15.7 Million to Advance Development of Novel Topical Treatments for Ophthalmic Diseaseshttps://modernod.com/news/oculis-raises-15-7-million-to-advance-development-of-novel-topical-treatments-for-ophthalmic-diseases/2476221/Oculis announced that it has successfully raised a further 15.5 million Swiss Franc ($15.7 million) in an extension of its Series B financing round, announced in January 2018, bringing the total raised to 35.5 million Swiss Franc. The extension round was led by funds managed by Tekla Capital Mana
- Orasis Announces the Appointment of Jeffry Weinhuff as Chairman of the Board of Directorshttps://modernod.com/news/orasis-announces-the-appointment-of-jeffry-weinhuff-as-chairman-of-the-board-of-directors/2479771/Orasis Pharmaceuticals announced the appointment of Jeffry Weinhuff as chairman of the board of directors. As a managing partner of Visionary Ventures, Mr. Weinhuff joins the Orasis board of directors in conjunction with the recent Series B financing led by Visionary Ventures, a venture capital f
- Dompé Receives FDA Approval of Oxervate, the First Drug for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-fda-approval-of-oxervate-a-first-in-class-treatment-of-neurotrophic-keratitis/2479916/The FDA has approved the first drug to treat neurotrophic keratitis, a rare and progressive eye disease that can lead to corneal scarring and vision loss. Oxervate (cenegermin-bkbj ophthalmic solution), which is manufactured by Italian pharmaceutical company Dompé, is based on cenegermin-b
- Bausch Health CEO: No Plans to Divest Bausch + Lombhttps://modernod.com/news/valeant-now-officially-bausch-health-companies-begins-trading-as-bhc/2480016/Valeant Pharmaceuticals International completed its name change to Bausch Health Companies. In an interview with Eyewire News to discuss the name change and direction of Bausch + Lomb, Bausch Health Chairman and CEO Joseph Papa said there are no plans to divest the eye care unit. “B
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko
- RetinAI and FVS Announce CE-MDR Certification for Co-Developed AI-Based DR Screening Algorithm, LuxIAhttps://modernod.com/news/retinai-and-fvs-announce-ce-mdr-certification-for-co-developed-ai-based-dr-screening-algorithm-luxia/2482773/RetinAI US and Fundación Ver Salud (FVS) have jointly announced that LuxIA, their co-developed AI algorithm for diabetic retinopathy (DR) screening, has successfully received CE-MDR certification as a Class IIb medical device under the European
- Ikerian Receives EU-MDR Certificate for Four Devices, its Ophthalmology Data Platform and AI Modelshttps://modernod.com/news/ikerian-receives-eu-mdr-certificate-for-four-devices-its-ophthalmology-data-platform-and-ai-models/2482328/Ikerian announced it has received a European Union Medical Device Regulation (EU-MDR) certificate as Class IIa medical devices for its RetinAI Discovery digital data platform, as well as AI-based models to identify and quantify retinal layers
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w